SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company distributor in the Dominican Republic, Laboratorios Franja, will be hosting training seminars for its customers and sales trainings for its staff in advance of launching the Company’s products throughout that country.
Co-Diagnostics recently selected Laboratorios Franja S.R.L. as the exclusive distributor of its diagnostics and Research Use Only (RUO) products throughout the Dominican Republic, a country of nearly 12 million people. The Company expects the initial product launch to include the CE-IVD Logix Smart™ tests for tuberculosis and Zika, other RUO products according to customer demand, and distribution of the CoDx Box™, a magnetic induction thermocycler with software optimized to run the Company’s polymerase chain reaction (PCR) products. Laboratorios Franja, an ISO 9001:2015 certified company, has also agreed to assist the Company with all local registration requirements needed to allow import and sale of its products in the Dominican Republic.
Mr. Cameron Gundry, Co-Diagnostics Director of Commercialization for Latin America, commented, “We are pleased with the progress made so far by Laboratorios Franja in generating interest for our products in the Dominican Republic, and completing the necessary registration steps for our products and company. We look forward to the valuable opportunities that this relationship creates for both parties, as well as the economic benefits of participating in the development and expansion of PCR technology across the Dominican Republic market.
Our official product launch into the Dominican Republic is a significant step for the commercialization of our company’s products, and one that shows our ability to build on the momentum we have been creating over the past several months. Our dedicated sales team continues to add to our distributor network worldwide in anticipation of following the same model in other countries that is now being implemented in the Dominican Republic, and those markets will be notified as similar training seminars and product demonstrations are scheduled.”
The training seminars will showcase demonstrations of the Company’s PCR products. They will be conducted by Company representatives and are scheduled to occur on November 27-28 at Laboratorios Franja’s headquarters in Santo Domingo, Dominican Republic with up to 20 laboratories and hospitals. Attendance is by invitation only. To request an invitation, contact the Company using the information at the bottom of this release, or Laboratorios Franja at email@example.com.
About Laboratorios Franja S.R.L.:
Laboratorios Franja is one of the most complete and efficient microbiology laboratories in Santo Domingo, offering distribution and sales of microbiology chemistry (cosmetics, medical equipment and cleaning) products, and food quality/safety, environmental microbiology and physical water chemistry analyses. Laboratorios Franja also markets and distributes high quality culture media, and related state-of-the-art technology. Owned and operated by Frank Reyes, the distributor has a highly qualified team of medical, lab staff and sales staff, and can be found online at www.laboratoriosfranja.com.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company with a proprietary diagnostic testing technology and development platform that intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and license the use of its platform to other non-competing developers.
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company’s products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company’s balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.